MUMBAI, India, Aug. 10 -- Intellectual Property India has published a patent application (202621072026 A) filed by Ansicht Voneden India on June 10, 2026, for Engineered Genetic Construct Compositions For Immune Modulation And Transplant Tolerance.
Inventor includes Dr. Ajinkya Inamdar.
The application for the patent was published on July 31, 2026, under issue no. 31/2026.
Abstract: ABSTRACT ENGINEERED GENETIC CONSTRUCT COMPOSITIONS FOR IMMUNE MODULATION AND TRANSPLANT TOLERANCE The instant disclosure provides engineered immune-modulator construct compositions for localised, targeted, and inflammation-gated suppression of pathological immune activation. A library of sixty-one constructs (SEQ ID NOs: 1 to 61; FIGS. 1 to 61) is organised by architecture into six classes: exosome-displayed depots presenting PD-L1, interleukin-10, interleukin-4, TIGIT, transforming growth factor beta 3, or CD39/CD73 cargo; tissue-targeted constructs bearing chemokine-receptor or collagen-sensing homing cassettes (CCR7, CCR4, CXCR5, CX3CR1, CCR9, CCR2B, DDR2); inflammation-gated tolerogenic switches in which a serum-response- element promoter or a programmed death-1 cytoplasmic-domain substitution drives a tolerogenic output upon sensing inflammation; graft-localised immune-shielding constructs expressing HLA-G or PD-L1; dual-input Gal4-UAS combination constructs; and receptor-fusion constructs joining a homing receptor to a transforming- growth-factor-beta-receptor-2 module. Each construct is deployable across vesicular, nucleic acid, viral, and cellular presentation formats, and any application-context assignment is non-restrictive. (
Disclaimer: Curated by HT Syndication.
